Clinical trials: Patients With Type 2 Diabetes
Oxidative Stress, Coronary Artery Disease
Efficacy of Pioglitazone on Myocardial Function in Patients Undergoing Coronary Stent Implantation.
The purpose of this study is to determine the effects of pioglitazone, once daily (QD), on heart functioning before, during and after stent implantation.
- Conditions
- Oxidative Stress, Coronary Artery Disease, Type 2 Diabetes
- Trial name
- NCT00771004
- Testing
- Pioglitazone
- Where
- 7 sites in Germany
- Volunteers
- 63 people
- Sponsor
- Takeda
Type 2 Diabetes, Obesity
A Prospective, Clinical Trial of the TANTALUS® System in Treatment of Obese to Morbidly Obese Patients
The objectives of this feasibility study are to evaluate the safety and functionality of the TANTALUS System with TANTALUS II IPG, to assess the effect of GCM signal application on trends of HbA1c, blood glucose and body weight…
- Trial name
- NCT00779363
- Testing
- rechargeable TANTALUS II
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- MetaCure (USA), Inc.
Diabetes, Diabetes Mellitus, Type 1
Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes
This trial is conducted in Europe. The aim of this observational study is to evaluate the glycaemic control in patients with type 1 or 2 diabetes using NovoMix® 30 or Levemir® under normal clinical practice conditions.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00665093
- Testing
- biphasic insulin aspart 30, insulin detemir
- Where
- North Macedonia
- Volunteers
- 1,569 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Nephropathy
A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED)
Evaluate the effect of Losartan in reducing kidney disease in patients with Non-insulin Dependent Diabetes and Nephropathy (kidney damage that usually accompanies late stage Diabetes Mellitus).
- Trial name
- NCT00308347
- Testing
- MK0954, losartan / Duration of Treatment: mean 3.4 years
- Volunteers
- 1,513 people
- Sponsor
- Organon and Co
Type 2 Diabetes, Overweight or Obesity
Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus
This study is designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of CT-996 in overweight/obese participants and participants with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT05814107
- Testing
- CT-996
- Where
- 2 sites in Australia, Mexico
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Carmot Australia First Pty Ltd
Hypercholesterolemia, Atherosclerosis
Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)
The study was designed to assess whether 6 weeks of co-administration of ezetimibe and simvastatin is more effective than simvastatin monotherapy in allowing patients in the CHD risk strata of the NCEP III guidelines to achieve…
- Trial name
- NCT00651014
- Testing
- Ezetimibe
- Volunteers
- 82 people
- Sponsor
- Organon and Co
Type 1 Diabetes, Type 2 Diabetes
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
The purpose of this study is to allow patients with specific needs for inhaled insulin to continue with inhaled insulin therapy using Technosphere Insulin after Exubera was withdrawn from the market.
- Trial name
- NCT01798914
- Testing
- Technosphere Insulin Inhalation Powder
- Where
- 14 sites in United States
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 2
A Study of LY2189265 in Japanese Patients With Type 2 Diabetes
The main purpose of this study is to assess dose-response characteristics in Japanese patients with Type 2 Diabetes taking LY2189265 monotherapy.
- Trial name
- NCT01001104
- Testing
- LY2189265
- Where
- 6 sites in Japan
- Volunteers
- 145 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus
A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control
To assess the impact on glucose control by inhaled insulin in patients with type 2 diabetes who are not well controlled on 2 or more oral anti-diabetic agents
- Trial name
- NCT00134147
- Testing
- Inhaled Insulin
- Where
- 121 sites in United States, Canada and 5 more
- Volunteers
- 1,100 people
- Sponsor
- Pfizer
Type 2 Diabetes
A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
The purpose of this clinical research study is to learn whether Saxagliptin can improve the body's ability to make its own insulin and lower blood sugar in people with type 2 diabetes
- Trial name
- NCT00374907
- Testing
- Saxagliptin, Metformin (blinded), Metformin (open-label)
- Where
- 3 sites in United States
- Volunteers
- 156 people
- Sponsor
- AstraZeneca
Diabetes Mellitus Type 2
Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice
This is a multicenter, randomised, open-label, crossover, 2-period comparative phase IV study. The primary objective is to compare the effect of dapagliflozin 10 mg once daily in combination with metformin at a daily dose of…
- Trial name
- FLORA (NCT02719132)
- Testing
- Dapagliflozin, Metformin
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Study in Patients With Type 2 Diabetes Mellitus
The purpose of this study is: To compare blood sugar control on LY2605541 with insulin glargine after 52 weeks of treatment. To compare the rate of night time low blood sugar episodes on LY2605541 with insulin glargine during 52…
- Trial name
- IMAGINE 2 (NCT01435616)
- Testing
- Glargine, LY2605541
- Where
- 167 sites in United States, Argentina and 21 more
- Volunteers
- 1,538 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus
The purpose of this trial is to examine the efficacy and safety of once-weekly LY2189265 in participants with type 2 diabetes mellitus who are not taking oral antidiabetic medication.
- Trial name
- NCT01558271
- Testing
- LY2189265, Liraglutide
- Where
- 14 sites in Japan
- Volunteers
- 492 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of the Safety and Pharmacokinetics of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes
The purpose of this study is to determine if T2-18C3, a true human monoclonal antibody that blocks inflammation, is safe to use in patients with type 2 diabetes.
- Trial name
- NCT01427699
- Testing
- T2-18C3 therapeutic antibody
- Where
- Switzerland
- Volunteers
- 7 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
Tolerability to HS-20004 With Titration Administration in Type 2 Diabetic Patients
This study is conducted in China. The aim of this trial is to assess the tolerability to HS-20004 with titration administration in type 2 diabetic patients.
- Trial name
- NCT02750007
- Testing
- HS-20004
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of TA-7284 as monotherapy in patients with type 2 Diabetes for 24 weeks administration.
- Trial name
- NCT01413204
- Testing
- TA-7284 Low, TA-7284 High
- Where
- 5 sites in Japan
- Volunteers
- 272 people
- Sponsor
- Tanabe Pharma Corporation
Type 2 Diabetes
Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes
The objective of this study is to evaluate the efficacy of MCI-196 in patients with Type 2 Diabetes based on the changes in blood glucose-related parameters and safety after 12 weeks administration in double-blind…
- Trial name
- NCT00497198
- Testing
- MCI-196
- Volunteers
- 183 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)
The purpose of this study is to determine if LY2189265 is effective in reducing hemoglobin A1c (HbA1c) and safe, as compared to Insulin Glargine in participants with Type 2 Diabetes.
- Trial name
- AWARD-2 (NCT01075282)
- Testing
- Insulin Glargine, LY2189265, Metformin
- Where
- 78 sites in Argentina, Australia and 18 more
- Volunteers
- 810 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus Type II
Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy
The aim of this pilot-study is to investigate the effect of Vildagliptin in comparison to glimepiride on beta cell function and the cardiovascular risk profile in patients previously treated with Metformin monotherapy.
- Trial name
- NCT01565096
- Testing
- Metformin, Vildagliptin, Glimepiride
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- ikfe-CRO GmbH
Type II Diabetes
Evaluation of Effects of Dibifree® on Regulation of Blood Sugar and HbA1c in Patients With Type II Diabetes
At present, diabetic patients mainly use drugs to control blood sugar. However, drugs have side effects and the control effect varies among individuals.
- Trial name
- NCT06224803
- Testing
- Compound plant extracts, Indigestible dextrin
- Where
- Taiwan
- Volunteers
- 56 people
- Sponsor
- Global Preventive Medicine Biotech Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.